| Titre : | Use of Fertility Drugs and Risk of Uterine Cancer : Results From a Large Danish Population-based Cohort Study. (2009) |
| Auteurs : | Allan JENSEN ; KJAER (Susanne-K) : DNK. Gynecologic Clinic. The Juliane Marie Center. Rigshospitalet. University of Copenhagen. Copenhagen. ; Heidi SHARIF |
| Type de document : | Article |
| Dans : | American journal of epidemiology (vol. 170, n° 11, 2009) |
| Pagination : | 1408-1414 |
| Langues: | Anglais |
| Mots-clés : | Utilisation ; Médicament ; Facteur risque ; Stérilité ; Risque ; Résultat ; Danemark ; Epidémiologie ; Population ; Utérus ; Homme ; Europe ; Cancer ; Appareil génital femelle |
| Résumé : | [BDSP. Notice produite par INIST-CNRS R0x888tJ. Diffusion soumise à autorisation]. Some epidemiologic studies have indicated that uterine cancer risk may be increased after use of fertility drugs. To further assess this association, the authors used data from a large cohort of 54,362 women diagnosed with infertility who were referred to Danish fertility clinics between 1965 and 1998. In a case-cohort study, rate ratios and 95% confidence intervals were used to assess the effects of 4 groups of fertility drugs on overall risk of uterine cancer after adjustment for potentially confounding factors. Through mid-2006,83 uterine cancers were identified. Ever use of any fertility drug was not associated with uterine cancer risk (rate ratio (RR)=1.10,95% confidence interval (CI) : 0.69,1.76). However, ever use of gonadotropins (follicle-stimulating hormone and human menopausal gonadotropin) increased uterine cancer risk (RR=2.21,95% CI : 1.08,4.50) ; the risk was primarily observed after 10 years of follow-up. Furthermore, uterine cancer risk increased with number of cycles of use for clomiphene (for>6 cycles, RR=1.96,95% CI : 1.03,3.72) and human chorionic gonadotropin (for>6 cycles, RR=2.18,95% CI : 1.16,4.08) but not for other gonadotropins. Use of gonadotropin-releasing hormone analogs was not associated with risk. Gonadotropins, and possibly clomiphene and human chorionic gonadotropin, may increase the risk of uterine cancer, with higher doses and longer follow-up leading to greater risk. |
Service Documentation EHESP
Me connecter
PORTAIL DOCUMENTAIRE
École des hautes études en santé publique
Catalogue
Multi-bases
Accueil
Sélection de la langue
Adresse
Service Documentation EHESPBibliothèque Rennes Avenue du Professeur Léon Bernard – CS 74312 – 35043 Rennes Cedex Bibliothèque MSSH Paris 20 avenue George Sand - 93210 La Plaine Saint-Denis
France
Bibliothèque Rennes : 02 99 02 29 50 Bibliothèque MSSH Paris : 02 99 02 24 50
contact